CNBC, Power Lunch Dr. Jon Cohen, BioReference Laboratories Executive Chairman, joins ‘Power Lunch’ to discuss the launch of drive-thru testing and how quickly it will produce results. Click here for original post on CNBC, Power Lunch
Search Results for: hair test
South Florida Business Journal BioReference Laboratories, a subsidiary of Miami-based Opko Health (Nasdaq: OPK), has begun accepting specimen from health care providers throughout the U.S. to test whether or not their patients have COVID-19. The lab launched testing Friday, expecting to start with about 1,000 to 2,000 tests a day. BioReference expects to eventually ramp […]
Press Release
OPKO Health’s BioReference Laboratories Offers Testing for Coronavirus Disease 2019 (COVID-19)
13
Mar
Mar
In partnership with NY State Department of Health, BioReference will provide COVID-19 testing for the first public drive-through testing facility on the East Coast COVID-19 tests now available for use by healthcare providers throughout the US ELMWOOD PARK, N.J., March 13, 2020 /PRNewswire/ — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), is now […]
Press Release
OPKO Health’s BioReference Laboratories to Introduce Coronavirus Disease (COVID-19) Test
05
Mar
Mar
COVID-19 test will aid healthcare professionals and public health authorities to identify patients infected with COVID-19 ELMWOOD PARK, N.J., March 05, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced it will offer a test for the novel coronavirus (2019-nCoV), a contagious virus that causes respiratory infection and has shown evidence of human-to-human […]
Press Release
BioReference Laboratories Showcases 2019 Growth through the Addition of Cutting Edge Tests, Greater Access to Services, and Optimized Patient Experience
19
Dec
Dec
ELMWOOD PARK, N.J., December 19, 2019 – BioReference Laboratories, Inc., an OPKO Health Company, along with its genetics and genomics laboratory, GeneDx, Inc., and oncology, urology and women’s health division, GenPath Diagnostics, are pleased to provide a 2019 business update, highlighting new tests that lead to faster diagnoses, payer relationships that provide greater access to […]
15
Nov
Nov
Medicare coverage for patients meeting certain criteria to begin as of December 30, 2019 MIAMI, Nov. 15, 2019 (GLOBE NEWSWIRE) — OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued its final Local Coverage Determination (LCD) for Medicare payments for the 4Kscore® test with defined coverage criteria, effective December 30, 2019. Full text of the […]
Geoff Monk promoted to President MIAMI, Jan. 07, 2019 – OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Jon R. Cohen, M.D. as Executive Chairman of BioReference Laboratories. BioReference, with its GeneDx unit, is the third largest clinical laboratory in the United States. OPKO also announced the promotion of Geoff Monk to President of BioReference. Mr. Monk joined BioReference as General […]
MIAMI, May 18, 2018 (GLOBE NEWSWIRE) — OPKO Health, Inc.(Nasdaq:OPK) today announced that Novitas Solutions, Inc. issued a draft local coverage determination (LCD) for the 4Kscore test®. The draft LCD is a proposed non-coverage policy for the 4Kscore test for Medicare and, prior to its effectiveness, is subject to a public comment period ending July 5, 2018. OPKO plans to submit comments during […]
Study of 11,506 men shows that healthy men with an abnormal PSA and a low 4Kscore test result can be safely monitored rather than undergo prostate biopsy MIAMI, March 16, 2018 (GLOBE NEWSWIRE) — OPKO Health, Inc.(NASDAQ:OPK) today announced that data from a landmark study of the 4Kscore® test entitled, “Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel […]
MIAMI, May 18, 2017 (GLOBE NEWSWIRE) — OPKO Health, Inc.(NASDAQ:OPK), announces that data from a prospective study conducted at Veteran Affairs (VA) hospitals confirming the 4Kscore test’s ability to accurately predict aggressive prostate cancer were presented in a podium presentation on May 16, 2017 at the 112thAmerican Urological Association (AUA) Annual Meeting in Boston. The study entitled, “An Independent, Multi-Institutional, Prospective […]
